Ron Leuty

UC Berkeley spinout lands $100 million for new approach to rare and chronic diseases.

Nektar and Lilly are heading for a fight over hair-loss treatments.

"We are not done," Rezolute CEO says after drug's clinical trial failure in congenital hyperinsulinism.

Fat-fighting biotech company soars: Investors sent Structure Therapeutics' stock flying high after the company disclosed results from two studies testing different doses of its oral GLP-1 drug.

Sam Altman's like all of us — he's aging. But a company he's backed wants it to stop. So could you pony up some cash at a $5 billion valuation?

Octave Bio lands massive deal with Quest Diagnostics that will expand reach of its multiple sclerosis tests

How this biotech company plans to bring its team together for less

Converted for biotech, Peninsula project lands 1st life sciences tenant years later

Data dump: How Kohler wants to turn your toilet into a health monitor

"A drug that stops kidney function decline is transformative," Vera Therapeutics founder and CEO Marshall Fordyce said.